|Antigen:||Phosphorylated Ser201 of Pax3|
|Accession ID:||P23760 (human), P24610 (mouse)|
|Molecular Weight:||1.415 kDa|
|Immunogen:||Peptide-KLH conjugate: KLH-CSERASAPQ(pSer)DEG|
|Purification Method:||Protein G|
|Buffer:||0.1M Sodium Phosphate, pH 7.4, 0.15M NaCl, 0.05% (w/v) Sodium Azide|
|Tested Applications:||WB (1:2000)|
Representative antibody recognition of Pax3(p201) by Western Blot
Bacterially expressed and purified wild-type GST-Pax3 was used as purified (left lanes) or was phosphorylated using an in vitro kinase assay and non-radioactive ATP (right lanes). The proteins were used for Western blot analysis using the anti-Pax3(p201) polyclonal antibody. A Coomassie stained gel demonstrates the presence of equal amounts of protein in the assay (top panel).
Adapted from: Dietz KN, et al. Int J Biochem Cell Biol. 2011 Jun;43(6):936-45.
- Dietz KN, Miller PJ, Iyengar AS, Loupe JM, Hollenbach AD. Identification of serines 201 and 209 as sites of Pax3 phosphorylation and the altered phosphorylation status of Pax3-FOXO1 during early myogenic differentiation. Int J Biochem Cell Biol. 2011 Jun;43(6):936-45.
- Loupe JM, Miller PJ, Ruffin DR, Stark MW, Hollenbach AD. Inhibiting phosphorylation of the oncogenic PAX3-FOXO1 reduces alveolar rhabdomyosarcoma phenotypes identifying novel therapy options. Oncogenesis. 2015 Mar 30;4:e145. doi: 10.1038/oncsis.2015.2.
If you publish research with this product, please let us know so we can cite your paper.